CN img
news
Your location:
Homepage
/
/
Company news
2022
03-23
小黑点

To ensure drug safety, the selection and maintenance of coating equipment cannot be ignored

In recent years, with the rapid development of the pharmaceutical industry, the coating equipment market has also ushered in good development opportunities. It is worth noting that while ushering in opportunities, fierce market competition also followed, and coating equipment companies began to face more challenges and new requirements. It is understood that in order to better ensure the stability of drugs, many coating equipment manufacturers have begun to improve and upgrade their equipment.
查看详情
2022
03-23
小黑点

The role of mesalamine

The colonic mucosa of patients with active UC has high levels of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4). Mesalazine can inhibit the synthesis of prostaglandins in a dose-dependent manner and reduce the release of PGE2 in human colonic mucosa.
查看详情
2022
03-25
小黑点

The State Food and Drug Administration Solicits Opinions on the New Regulations on Review Procedures to...

With the encouragement and support of relevant laws, regulations and policies, my country's innovative drug research and development has achieved outstanding results. According to statistics, in the past five years, a total of 59 countries in my country have been approved for marketing of Class 1 new drugs, and 22 last year, a new high. The author was informed that, in order to encourage the research and creation of new drugs and speed up the review of innovative drugs, the Center for Drug Evaluation of the State Food and Drug Administration recently issued a review on the "Center for Drug Evaluation to Accelerate the Review of Innovative Drug Marketing Applications (Trial) (Draft for Comment)". (hereinafter referred to as the "Working Procedures") for public comments.
查看详情
Previous page
1

Address:

No.1 Kangan Road, Economic Development Zone, Liyang, Jiangsu, China.

E-mail:

Service Hotline:

Fax:

86-519-80691305

Mobile:

微信 微信

Copyright© 2022 Jiangsu Jubang Pharmaceutical Co., Ltd.  Powered by www.300.cn​